Stock CDTX CIDARA THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Cidara Therapeutics, Inc.

Equities

CDTX

US1717571079

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-24 pm EDT 		5-day change 1st Jan Change
12.29 USD +19.90% Intraday chart for Cidara Therapeutics, Inc. -14.91% -22.61%
Apr. 24 Cidara Therapeutics Shares Surge 42% After Re-Acquiring Flu Asset DJ
Apr. 23 Cidara Therapeutics Q4 Loss Narrows as Sales Rise; Shares Surge Premarket MT

Evolution of the average Target Price on Cidara Therapeutics, Inc.

Price target over the last 5 years

History of analyst recommendation changes

c635c15b69d5d6.jS-ilxSE5SYcr5WICX9tnSjFQE1r0BVMgCMSuZpq1dQ.-ELS1UD1iUlJ3uTdQS0cxGahMAgpgV4b6xFc3P0SoZzDWfT9IbafV0X8-g~e8ecdd7333ac1ae3417cefad4bba5699

Analyst Recommendations on Cidara Therapeutics, Inc.

HC Wainwright Adjusts Cidara Therapeutics' Price Target to $6 From $6.50, Keeps Buy Rating MT
Atlanta Fed President's Comments on Rate Hikes Continue to Boost Sentiment, Driving Cautious Gains for US Equity Futures MT
HC Wainwright Adjusts Cidara Therapeutics' Price Target to $6.50 From $6, Maintains Buy Rating MT
Wedbush Drops Coverage of Cidara Therapeutics MT
HC Wainwright Adjusts Cidara Therapeutics Price Target to $6 From $7.50, Maintains Buy Rating MT
Maxim Group Adjusts Cidara Therapeutics Price Target to $3 From $5, Maintains Buy Rating MT
Wedbush Lifts Cidara Therapeutics' Price Target to $6 From $5 on Echinocandin Rezafungin Trial Data; Outperform Rating Kept MT
CIDARA THERAPEUTICS : Aegis Capital Adjusts Cidara Therapeutics PT to $8 From $9, Maintains Buy Rating MT
CIDARA THERAPEUTICS : Wedbush Adjusts Price Target for Cidara Therapeutics to $5 From $4, Maintains Outperform Rating MT
CIDARA THERAPEUTICS : Aegis Capital Starts Cidara Therapeutics at Buy With $9 Price Target MT
CIDARA THERAPEUTICS : Wedbush Adjusts Price Target on Cidara Therapeutics to $4 From $5, Keeps Outperform Rating MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
10.25 USD
Average target price
90 USD
Spread / Average Target
+778.05%
High Price Target
120 USD
Spread / Highest target
+1,070.73%
Low Price Target
60 USD
Spread / Lowest Target
+485.37%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Cidara Therapeutics, Inc.

HC Wainwright
Wedbush
Maxim
Aegis Capital

Ratings for Cidara Therapeutics, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. CDTX Stock
  4. Consensus Cidara Therapeutics, Inc.